encephalopathy: Broadening the phenotype and evaluating treatment and outcome.
- Authors
- Danti, Federica Rachele; Galosi, Serena; Romani, Marta; Montomoli, Martino; Carss, Keren J; Raymond, F Lucy; Parrini, Elena; Bianchini, Claudia; McShane, Tony; Dale, Russell C; Mohammad, Shekeeb S; Shah, Ubaid; Mahant, Neil; Ng, Joanne; McTague, Amy; Samanta, Rajib; Vadlamani, Gayatri; Valente, Enza Maria; Leuzzi, Vincenzo; Kurian, Manju A; Guerrini, Renzo
- Year
- 2017
- Journal
- Neurology. Genetics
- PMID
- 28357411
- DOI
- 10.1212/NXG.0000000000000143
- PMCID
- PMC5362187
OBJECTIVE: To describe better the motor phenotype, molecular genetic features, and clinical course of -related disease. METHODS: We reviewed clinical information, video recordings, and neuroimaging of a newly identified cohort of 7 patients with de novo missense and splice site mutations, detected by next-generation sequencing techniques. RESULTS: Patients first presented in early childhood (median age of presentation 10 months, range 0-48 months), with a wide range of clinical symptoms ranging from severe motor and cognitive impairment with marked choreoathetosis, self-injurious behavior, and epileptic encephalopathy to a milder phenotype, featuring moderate developmental delay associated with complex stereotypies, mainly facial dyskinesia and mild epilepsy. Hyperkinetic movements were often exacerbated by specific triggers, such as voluntary movement, intercurrent illnesses, emotion, and high ambient temperature, leading to hospital admissions. Most patients were resistant to drug intervention, although tetrabenazine was effective in partially controlling dyskinesia for 2/7 patients. Emergency deep brain stimulation (DBS) was life saving in 1 patient, resulting in immediate clinical benefit with complete cessation of violent hyperkinetic movements. Five patients had well-controlled epilepsy and 1 had drug-resistant seizures. Structural brain abnormalities, including mild cerebral atrophy and corpus callosum dysgenesis, were evident in 5 patients. One patient had a diffuse astrocytoma (WHO grade II), surgically removed at age 16. CONCLUSIONS: Our findings support the causative role of mutations in an expanded spectrum of early-onset epilepsy and movement disorders, frequently exacerbated by specific triggers and at times associated with self-injurious behavior. Tetrabenazine and DBS were the most useful treatments for dyskinesia.
Membrane topology modeling of GNAO1Membrane topology was predicted using the Protter online tool29 (P09471, GNAO_HUMAN). Known GNAO1 missense mutations are indicated in green, the deletion is in yellow. Mutations found in this report and already described in the literature are indicated in light blue, novel mutations in red.
LLM interpretation
This is a membrane topology diagram of the GNAO1 protein, showing its orientation relative to the extracellular (Extra) and intracellular (Intra) spaces. The protein sequence is mapped with various mutations color-coded by their source: green for known missense mutations, yellow for a known deletion, light blue for mutations found in both this report and literature, and red for novel mutations. Specific amino acid substitutions and deletions are labeled with their corresponding residue positions and patient references.
MRI characteristics of 7 patients with GNAO1 mutationsFor patients 1β6, a set of 3 images including an axial (A, D, G, J, M, and S), coronal (B, E, H, K, N, and T), and sagittal midline (C, F, I, L, O, and U) sequences is shown. For patient 5, in addition, 1 axial (P) and 2 coronal (Q and R) images are shown to illustrate better the neoplastic lesion in the left frontal lobe (arrows). For patient 7, axial images of 2 different investigations (V and W) and a sagittal image are shown to illustrate better the progression of atrophic changes. Images are at 1.5β3T. Images AβE, G, J, K, N, O, Q, S, T, and W are T2 weighted. Images F, I, L, U, and X are T1 weighted. Images H, M, P, and R are acquired as fluid attenuation inversion recovery (FLAIR) sequences. Patient 1: axial and coronal images show mild ventricular enlargement in the frontal horns, with concomitant hypoplasia of the caudate nuclei. The sagittal section shows a thin corpus callosum. Patient 2: axial and coronal images show mild ventricular enlargement in the frontal horns, with mild hypoplasia of the caudate nuclei, likewise seen in patient 1. The sagittal section shows a thin corpus callosum and a hypoplastic inferior vermis. Patient 3: axial and coronal images show moderate cortical atrophy, with ventricular enlargement and small caudate nuclei. The sagittal image shows a dysmorphic corpus callosum. Patient 4: no structural abnormality is visible on MRI. Patient 5: MRI shows an isolated abnormality (arrows) involving the anterolateral aspect of the left frontal lobe, including the cortex and underlying white matter, with increased signal intensity on both T2 and FLAIR images. Histopathology, after surgical removal of the lesion, showed characteristics consistent with a diffuse astrocytoma (WHO grade 2). Patient 6: axial and coronal images show dilated lateral ventricles; the sagittal cut shows a thin corpus callosum. Patient 7: the first axial MRI at age 2 (V) is normal, but a follow-up study at age 16 (W) shows loss of brain volume in generalized distribution. No abnormalities in the brainstem and cerebellum are visible in the sagittal image at age 16 (X).
LLM interpretation
This figure presents a series of MRI brain scans (T2-weighted, T1-weighted, and FLAIR sequences) for seven patients with *GNAO1* mutations, displayed in axial, coronal, and sagittal views. The images illustrate varying structural characteristics, including ventricular enlargement, caudate nuclei hypoplasia, and a thin corpus callosum in several patients, while Patient 4 shows no structural abnormalities. Specific findings include a neoplastic lesion in the left frontal lobe of Patient 5 (indicated by arrows) and progressive generalized brain volume loss in Patient 7 between two time points (images V and W).
| # | Section | Preview |
|---|---|---|
| 20 | DISCUSSION | Long-term outcome of early-onset GNAO1-related disease remains yet to be determined. We would⦠|
No entities extracted from this document yet.
No uploaded files.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| AlkufriF, ShaagA, Abu-LibdehB, ElpelegO Deleterious mutation in GPR88 is associated with chorea, speech delay, and learning disabilities. Neurol Genet 2016;2:e64 doi: 10.1212/NXG.0000000000000064.2712348610.1212/NXG.0000000000000064PMC4830197 | β | β | β |
| AnanthAL, Robichaux-ViehoeverA, KimYM, et al Clinical course of six children with GNAO1 mutations causing a severe and distinctive movement disorder. Pediatr Neurol 2016;59:81β84.2706805910.1016/j.pediatrneurol.2016.02.018 | β | β | β |
| ChungHJ, QianX, EhlersM, JanYN, JanLY Neuronal activity regulates phosphorylation-dependent surface delivery of G protein-activated inwardly rectifying potassium channels. Proc Natl Acad Sci USA 2009;106:629β634.1911819810.1073/pnas.0811615106PMC2613039 | β | β | β |
| DhamijaR, MinkJW, ShahBB, GoodkinHP GNAO1-associated movement disorder. Mov Disord Clin Pract 2016;3:615β617.10.1002/mdc3.12344PMC635346930838255 | β | β | β |
| EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project, Epi4K Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 2014;95:360β370.2526265110.1016/j.ajhg.2014.08.013PMC4185114 | β | β | β |
| Garcia-MarcosM, GhoshP, FarquharMG Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene 2011;30:2691β2696.2131792310.1038/onc.2010.645PMC3349449 | β | β | β |
| GawlinskiP, PosmykR, GambinT, et al PEHO syndrome may represent phenotypic expansion at the severe end of the early-onset encephalopathies. Pediatr Neurol 2016;60:83β87.2734302610.1016/j.pediatrneurol.2016.03.011PMC5125779 | β | β | β |
| HamidE, ChurchE, WellsCA, ZurawskiZ, HammHE, AlfordS Modulation of neurotransmission by GPCRs is dependent upon the microarchitecture of the primed vesicle complex. J Neurosci 2014;34:260β274.2438128710.1523/JNEUROSCI.3633-12.2014PMC3866488 | β | β | β |
| HelbigKL, Farwell HagmanKD, ShindeDN, et al Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med 2016;18:898β905.2679559310.1038/gim.2015.186 | β | β | β |
| HolzGG, RaneSG, DunlapK GTP-binding proteins mediate transmitter inhibition of voltage-dependent calcium channels. Nature 1986;319:670β672.241975710.1038/319670a0PMC2926796 | β | β | β |
| JiangM, GoldMS, BoulayG, et al Multiple neurological abnormalities in mice deficient in the G protein Go. Proc Natl Acad Sci USA 1998;95:3269β3274.950125210.1073/pnas.95.6.3269PMC19731 | β | β | β |
| KehrlJM, SahayaK, DaltonHM, et al Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)? Mamm Genome 2014;25:202β210.2470028610.1007/s00335-014-9509-zPMC4042023 | β | β | β |
| KulkarniN, TangS, BhardwajR, BernesS, GrebeTA Progressive movement disorder in brothers carrying a GNAO1 mutation responsive to deep brain stimulation. J Child Neurol 2016;31:211β214.2606030410.1177/0883073815587945 | β | β | β |
| LawCY, ChangSTL, ChoSY, et al Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy. Clin Chim Acta 2015;451:292β296.2648525210.1016/j.cca.2015.10.011 | β | β | β |
| LiJ, CaiT, JiangY, et al Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database. Mol Psychiatry 2016;21:298.2593940310.1038/mp.2015.58 | β | β | β |
| MarcΓ©-GrauA, DaltonJ, LΓ³pez-PisΓ³nJ, et al GNAO1 encephalopathy: further delineation of a severe neurodevelopmental syndrome affecting females. Orphanet J Rare Dis 2016;11:1β9.2707279910.1186/s13023-016-0416-0PMC4830060 | β | β | β |
| MenkeLA, EngelenM, AldersM, OdekerkenVJ, BaasF, CobbenJM Recurrent GNAO1 mutations associated with developmental delay and a movement disorder. J Child Neurol 2016; 31:1598β1601.2762501110.1177/0883073816666474 | β | β | β |
| NakamuraK, KoderaH, AkitaT, et al De Novo mutations in GNAO1, encoding a Galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy. Am J Hum Genet 2013;93:496β505.2399319510.1016/j.ajhg.2013.07.014PMC3769919 | β | β | β |
| OmasitsU, AhrensCH, MΓΌllerS, WollscheidB Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 2014;30:884β886.2416246510.1093/bioinformatics/btt607 | β | β | β |
| PΓ©rez-RamΓrezM, HernΓ‘ndez-JimΓ©nezAJ, Guerrero-GuerreroA, et al Genomics and epigenetics: a study of ependymomas in pediatric patients. Clin Neurol Neurosurg 2016;144:53β58.2697129610.1016/j.clineuro.2016.02.041 | β | β | β |
| RosenbaumDM, RasmussenSG, KobilkaBK The structure and function of G-protein-coupled receptors. Nature 2009;459:356β363.1945871110.1038/nature08144PMC3967846 | β | β | β |
| SaitsuH, FukaiR, Ben-ZeevB, et al Phenotypic spectrum of GNAO1 variants: epileptic encephalopathy to involuntary movements with severe developmental delay. Eur J Hum Genet 2016;24:129β134.2596663110.1038/ejhg.2015.92PMC4795232 | β | β | β |
| StraikerAJ, BordenCR, SullivanJM G-protein alpha subunit isoforms couple differentially to receptors that mediate presynaptic inhibition at rat hippocampal synapses. J Neurosci 2002;22:2460β2468.1192341010.1523/JNEUROSCI.22-07-02460.2002PMC6758342 | β | β | β |
| TalvikI, MollerRS, VaherM, et al Clinical phenotype of de novo GNAO1 mutation: case report and review of literature. Child Neurol Open 2015;2:1β7.10.1177/2329048X15583717PMC541703328503590 | β | β | β |
| ValenzuelaD, HanX, MendeU, et al G alpha(o) is necessary for muscarinic regulation of Ca2+ channels in mouse heart. Proc Natl Acad Sci USA 1997;94:1727β1732.905084610.1073/pnas.94.5.1727PMC19984 | β | β | β |
| YangH, WangK Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc 2015;10:1556β1566.2637922910.1038/nprot.2015.105PMC4718734 | β | β | β |
| YilmazS, TurhanT, CeylanerS, GΓΆkbenS, TekgulH, SerdarogluG Excellent response to deep brain stimulation in a young girl with GNAO1-related progressive choreoathetosis. Childs Nerv Syst 2016;32:1567β1568.2727828110.1007/s00381-016-3139-6 | β | β | β |
| ZhuX, PetrovskiS, XieP, et al Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Genet Med 2015;17:774β781.2559097910.1038/gim.2014.191PMC4791490 | β | β | β |
| ZupancicK, BlejecA, HermanA, et al Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach. Radiol Oncol 2014;48:257β266.2517724010.2478/raon-2014-0014PMC4110082 | β | β | β |
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genome-wide association study of stimulant dependence. | 2021 | 34226506 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Implementation of Paediatric Deep Brain Stimulation: Experience from an Australian Tertiary Centre. | Barnacoat JM et al. | β | 2026 | β |
| Decoding GNAO1 mutations using <i>Caenorhabditis elegans</i> model system: past approaches and future prospectives. | Yadav S et al. | β | 2025 | β |
| Exploring the Impact of Dyskinetic Crises in GNAO1-Related Disorders: A Survey for Parents and Caregivers. | DomΓnguez-Carral J et al. | β | 2025 | β |
| GNAO1 overexpression promotes neural differentiation of glioma stem-like cells and reduces tumorigenicity through TRIM21/CREB/HES1 axis. | Sun B et al. | β | 2025 | β |
| Identification of three novel GNAO1 variants in a Chinese cohort with GNAO1 encephalopathy: expanding the clinical and genetic spectrum. | Mei D et al. | β | 2025 | β |
| Neuronal oscillatory imbalances in GNAO1-related disorders associated with disease severity. | Wang T et al. | β | 2025 | β |
| Severe upper airway dysfunction in GNAO1-related disorders. | Bernardi K et al. | β | 2025 | β |
| The Spectrum of GNAO1 Mutation Can Include Childhood-Onset Isolated Generalized Dystonia. | Chowdhury S et al. | β | 2025 | β |
| AAV9-Mediated Intrastriatal Delivery of <i>GNAO1</i> Reduces Hyperlocomotion in <i>Gnao1</i> Heterozygous R209H Mutant Mice. | Roy AJ et al. | β | 2024 | β |
| CB1R activates the epilepsy-associated protein Go to regulate neurotransmitter release and synaptic plasticity in the cerebellum. | Choi JM et al. | β | 2024 | β |
| Clinical and Molecular Profiling in GNAO1 Permits Phenotype-Genotype Correlation. | Lasa-Aranzasti A et al. | β | 2024 | β |
| Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties. | Benedetti MC et al. | β | 2024 | β |
| Deep Brain Stimulation for GNAO1-Associated Dystonia: A Systematic Review and Meta-Analysis. | Decraene B et al. | β | 2024 | β |
| Dyskinetic crisis in <i>GNAO1</i>-related disorders: clinical perspectives and management strategies. | DomΓnguez Carral J et al. | β | 2024 | β |
| Gnao1 is a molecular switch that regulates the Rho signaling pathway in differentiating neurons. | Taira R et al. | β | 2024 | β |
| Molecular Dynamic Simulations to Determine Individualized Therapy: Tetrabenazine for the GNAO1 Encephalopathy E246K Variant. | Falsaperla R et al. | β | 2024 | β |
| Chromosome-scale genomes reveal genomic consequences of inbreeding in the South China tiger: A comparative study with the Amur tiger. | Zhang L et al. | β | 2023 | β |
| Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties | Benedetti MC et al. | β | 2023 | β |
| [Encephalopathy GNAO1]. | Bobylova MY et al. | β | 2023 | β |
| GNAO1-related movement disorder: An update on phenomenology, clinical course, and response to treatments. | Novelli M et al. | β | 2023 | β |
| GNAO1-related neurodevelopmental disorder: Literature review and caregiver survey. | JoJo Yang QZ et al. | β | 2023 | β |
| GNAO1-related Neurodevelopmental Disorder Presenting as Acute Encephalitis Syndrome: A Phenotypic Expansion. | Panda PK et al. | β | 2023 | β |
| Molecular and in silico analyses of SYN III gene variants in autism spectrum disorder. | Baris RO et al. | β | 2023 | β |
| Phenotypes in children with <i>GNAO1</i> encephalopathy in China. | Li Y et al. | β | 2023 | β |
| Phenotypic Assessment of Pathogenic Variants in <i>GNAO1</i> and Response to Caffeine in <i>C. elegans</i> Models of the Disease. | Di Rocco M et al. | β | 2023 | β |
| Phenotypic Diversity in GNAO1 Patients: A Comprehensive Overview of Variants and Phenotypes. | SΓ‘ez GonzΓ‘lez M et al. | β | 2023 | β |
| Severity of GNAO1-Related Disorder Correlates with Changes in G-Protein Function. | DomΓnguez-Carral J et al. | β | 2023 | β |
| Visual Function in Children with GNAO1-Related Encephalopathy. | Gambardella ML et al. | β | 2023 | β |
| An intronic GNAO1 variant leading to in-frame insertion cause movement disorder controlled by deep brain stimulation. | Miyamoto S et al. | β | 2022 | β |
| Both subthalamic and pallidal deep brain stimulation are effective for <i>GNAO1</i>-associated dystonia: three case reports and a literature review. | Liu Y et al. | β | 2022 | β |
| Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia. | Di Rocco M et al. | β | 2022 | β |
| DBS emergency surgery for treatment of dystonic storm associated with rhabdomyolysis and acute colitis in DYT-GNAO1. | Chaib H et al. | β | 2022 | β |
| Deep brain stimulation in a young child with <i>GNAO1</i> mutation - Feasible and helpful. | Fung EL et al. | β | 2022 | β |
| Genetic diagnosis of basal ganglia disease in childhood. | Baide-Mairena H et al. | β | 2022 | β |
| Genetic modeling of GNAO1 disorder delineates mechanisms of GΞ±o dysfunction. | Wang D et al. | β | 2022 | β |
| Gonadal mosaicism in GNAO1 causing neurodevelopmental disorder with involuntary movements; two additional variants. | Al Masseri Z et al. | β | 2022 | β |
| Highlighting the Dystonic Phenotype Related to GNAO1. | Wirth T et al. | β | 2022 | β |
| Motor, epileptic, and developmental phenotypes in genetic disorders affecting G protein coupled receptors-cAMP signaling. | Galosi S et al. | β | 2022 | β |
| Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation. | Silachev D et al. | β | 2022 | β |
| Presenting Patterns of Genetically Determined Developmental Encephalopathies With Epilepsy and Movement Disorders: A Single Tertiary Center Retrospective Cohort Study. | Mastrangelo M et al. | β | 2022 | β |
| Reflex seizures in rare monogenic epilepsies. | Krygier M et al. | β | 2022 | β |
| The Genetic Landscape of Complex Childhood-Onset Hyperkinetic Movement Disorders. | PΓ©rez-DueΓ±as B et al. | β | 2022 | β |
| The synaptic scaffold protein MPP2 interacts with GABAA receptors at the periphery of the postsynaptic density of glutamatergic synapses. | Schmerl B et al. | β | 2022 | β |
| A Retrospective Longitudinal Study in a Cohort of Children With Dyskinetic Cerebral Palsy Treated With Tetrabenazine. | Scalise R et al. | β | 2021 | β |
| Current challenges in the pathophysiology, diagnosis, and treatment of paroxysmal movement disorders. | Delorme C et al. | β | 2021 | β |
| Early-Onset Developmental and Epileptic Encephalopathies of Infancy: An Overview of the Genetic Basis and Clinical Features. | Morrison-Levy N et al. | β | 2021 | β |
| Emerging and converging molecular mechanisms in dystonia. | Gonzalez-Latapi P et al. | β | 2021 | β |
| Exome sequencing in paediatric patients with movement disorders. | Kwong AK et al. | β | 2021 | β |
| Genetic Dystonias: Update on Classification and New Genetic Discoveries. | Keller Sarmiento IJ et al. | β | 2021 | β |
| Genome-wide association study of stimulant dependence. | Cox J et al. | β | 2021 | β |
| Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia. | Song L et al. | β | 2021 | β |
| Neuromonitoring in Neonatal-Onset Epileptic Encephalopathies. | Trollmann R | β | 2021 | β |
| Paroxysmal Movement Disorders. | Harvey S et al. | β | 2021 | β |
| Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies. | Balestrini S et al. | β | 2021 | β |
| Rett Syndrome Spectrum in Monogenic Developmental-Epileptic Encephalopathies and Epilepsies: A Review. | Spagnoli C et al. | β | 2021 | β |
| Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis. | Artusi CA et al. | β | 2020 | β |
| Dysregulation of Exosome Cargo by Mutant Tau Expressed in Human-induced Pluripotent Stem Cell (iPSC) Neurons Revealed by Proteomics Analyses. | Podvin S et al. | β | 2020 | β |
| GNAO1 organizes the cytoskeletal remodeling and firing of developing neurons. | Akamine S et al. | β | 2020 | β |
| Mice with <i>GNAO1</i> R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone. | Larrivee CL et al. | β | 2020 | β |
| Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome. | Tisch S et al. | β | 2020 | β |
| Principles of Medical and Surgical Treatment of Cerebral Palsy. | Chin EM et al. | β | 2020 | β |
| Spectrum of movement disorders in GNAO1 encephalopathy: in-depth phenotyping and case-by-case analysis. | Kim SY et al. | β | 2020 | β |
| The expanding spectrum of movement disorders in genetic epilepsies. | Papandreou A et al. | β | 2020 | β |
| Brain Imaging-Guided Analysis Reveals DNA Methylation Profiles Correlated with Insular Surface Area and Alcohol Use Disorder. | Zhao Y et al. | β | 2019 | β |
| Current therapies and therapeutic decision making for childhood-onset movement disorders. | Mohammad SS et al. | β | 2019 | β |
| Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study. | Carecchio M et al. | β | 2019 | β |
| GNAO1 mutation presenting as dyskinetic cerebral palsy. | Malaquias MJ et al. | β | 2019 | β |
| Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation. | Benato A et al. | β | 2019 | β |
| Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes. | Feng H et al. | β | 2019 | β |
| Paroxysmal movement disorders - practical update on diagnosis and management. | De Gusmao CM et al. | β | 2019 | β |
| Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. | Schirinzi T et al. | β | 2019 | β |
| Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region. | Kelly M et al. | β | 2019 | β |
| Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia. | Koy A et al. | β | 2018 | β |
| GNAO1 Mutation-Induced Pediatric Dystonic Storm Rescue With Pallidal Deep Brain Stimulation. | Honey CM et al. | β | 2018 | β |
| Postsynaptic movement disorders: clinical phenotypes, genotypes, and disease mechanisms. | Abela L et al. | β | 2018 | β |
| Emerging Monogenic Complex Hyperkinetic Disorders. | Carecchio M et al. | β | 2017 | β |